TY - JOUR
T1 - Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up
T2 - A five-year review
AU - Borkar, Durga S.
AU - Lacouture, Mario E.
AU - Basti, Surendra
N1 - Funding Information:
Acknowledgments Dr. Basti is supported by the IDP Foundation and the Robert H. Lurie Comprehensive Cancer Center at Northwestern University. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the IDP Foundation and the Robert H. Lurie Comprehensive Cancer Center. The Department of Ophthalmology, Northwestern University Feinberg School of Medicine, is supported by an unrestricted grant from Research to Prevent Blindness, NY.
PY - 2013/4
Y1 - 2013/4
N2 - Purpose: Epidermal growth factor receptor (EGFR) inhibitors and kinases are commonly used in the treatment regimen of various solid tumors including non-small cell lung, colorectal, head and neck, breast, and pancreatic cancers. The aim of this study is to describe common ocular adverse effects associated with EGFR inhibitor treatment, outline successful management options, and provide data on intermediate-term follow-up of these patients. Methods: A retrospective chart review was performed of all patients presenting to the ophthalmology clinic with an adverse ocular effect while on an EGFR inhibitor. Duration of EGFR inhibitor treatment, symptoms, diagnosis, and treatment information were collected. Statistical analyses were done to ascertain differences in adverse effects based on duration and type of EGFR inhibitor treatment using the Fisher exact test. Results: The two most common EGFR inhibitors in this group of patients were erlotinib and cetuximab. The most common adverse ocular effects for patients on EGFR inhibitors were dysfunctional tear syndrome (DTS), followed by blepharitis and eyelash changes (trichomegaly and trichiasis). Two patients had epithelial defects (corneal abrasions). There was no significant difference in adverse effects based on specific EGFR inhibitor medication or duration of treatment. Almost all patients were successfully managed with treatment regimens that we have outlined in this paper. Intermediate-term follow-up (range 6-17 months) showed a persistence of DTS and eyelash changes. Conclusion: We present what is, to our knowledge, the largest reported cohort of patients with ocular toxicities from EGFR inhibitors - the spectrum of eye toxicities, their management, and the intermediate-term follow-up of patients with eye toxicities. Awareness of this information is important for oncologists and oncology nurses to facilitate proper counseling and management/referral of patients developing eye toxicity while on EGFR inhibitors.
AB - Purpose: Epidermal growth factor receptor (EGFR) inhibitors and kinases are commonly used in the treatment regimen of various solid tumors including non-small cell lung, colorectal, head and neck, breast, and pancreatic cancers. The aim of this study is to describe common ocular adverse effects associated with EGFR inhibitor treatment, outline successful management options, and provide data on intermediate-term follow-up of these patients. Methods: A retrospective chart review was performed of all patients presenting to the ophthalmology clinic with an adverse ocular effect while on an EGFR inhibitor. Duration of EGFR inhibitor treatment, symptoms, diagnosis, and treatment information were collected. Statistical analyses were done to ascertain differences in adverse effects based on duration and type of EGFR inhibitor treatment using the Fisher exact test. Results: The two most common EGFR inhibitors in this group of patients were erlotinib and cetuximab. The most common adverse ocular effects for patients on EGFR inhibitors were dysfunctional tear syndrome (DTS), followed by blepharitis and eyelash changes (trichomegaly and trichiasis). Two patients had epithelial defects (corneal abrasions). There was no significant difference in adverse effects based on specific EGFR inhibitor medication or duration of treatment. Almost all patients were successfully managed with treatment regimens that we have outlined in this paper. Intermediate-term follow-up (range 6-17 months) showed a persistence of DTS and eyelash changes. Conclusion: We present what is, to our knowledge, the largest reported cohort of patients with ocular toxicities from EGFR inhibitors - the spectrum of eye toxicities, their management, and the intermediate-term follow-up of patients with eye toxicities. Awareness of this information is important for oncologists and oncology nurses to facilitate proper counseling and management/referral of patients developing eye toxicity while on EGFR inhibitors.
KW - Drug-induced blepharitis
KW - Ocular toxicities of EGFR inhibitors
KW - Trichomegaly
UR - http://www.scopus.com/inward/record.url?scp=84879799977&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879799977&partnerID=8YFLogxK
U2 - 10.1007/s00520-012-1645-y
DO - 10.1007/s00520-012-1645-y
M3 - Article
C2 - 23151647
AN - SCOPUS:84879799977
SN - 0941-4355
VL - 21
SP - 1167
EP - 1174
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 4
ER -
